Tybost
NDC Package 61958-1402-1

11-digit billing NDC: 61958140201

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Tybost is the concomitant use of TYBOST with atazanavir or darunavir and the following drugs is contraindicated due to the potential for serious and/or life-threatening events or loss of therapeutic effect [see Drug Interactions (7.3) and Clinical Pharmacology (12.3)].Alpha 1-adrenoreceptor antagonist: alfuzosinAntianginal: ranolazineAntiarrhythmic: dronedaroneAnticonvulsants: carbamazepine, phenobarbital, phenytoinAnti-gout: colchicineAntimycobacterial: rifampinAntineoplastics: irinotecanThese contraindications apply only to TYBOST coadministered with atazanavirAntipsychotics: lurasidone, pimozideErgot Derivatives: dihydroergotamine, ergotamine, methylergonovineHerbal Products: St. Marketed by Gilead Sciences, Inc., this product is identified by NDC 61958-1402 and is authorized under FDA application NDA203094.

Identification & Billing

NDC Package Code
61958-1402-1
Package Description
30 TABLET, FILM COATED in 1 BOTTLE
Product Code
11-Digit Billing Format
61958140201
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Tybost
Dosage Form
-
Usage Information
The concomitant use of TYBOST with atazanavir or darunavir and the following drugs is contraindicated due to the potential for serious and/or life-threatening events or loss of therapeutic effect [see Drug Interactions (7.3) and Clinical Pharmacology (12.3)].Alpha 1-adrenoreceptor antagonist: alfuzosinAntianginal: ranolazineAntiarrhythmic: dronedaroneAnticonvulsants: carbamazepine, phenobarbital, phenytoinAnti-gout: colchicineAntimycobacterial: rifampinAntineoplastics: irinotecanThese contraindications apply only to TYBOST coadministered with atazanavirAntipsychotics: lurasidone, pimozideErgot Derivatives: dihydroergotamine, ergotamine, methylergonovineHerbal Products: St. John's wort (Hypericum perforatum)Hormonal Contraceptives: drospirenone/ ethinyl estradiolLipid-modifying Agents: lomitapide, lovastatin, simvastatinNon-nucleoside Reverse Transcriptase Inhibitor: nevirapinePhosphodiesterase-5 (PDE-5) Inhibitor: sildenafil when administered as Revatio® for the treatment of pulmonary arterial hypertensionProtease Inhibitor: indinavirSedative/hypnotics triazolam, orally administered midazolam

Regulatory & Marketing

Labeler Name
Gilead Sciences, Inc.
FDA Application #
NDA203094
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
06-20-2025
End Marketing Date
09-25-2025
Listing Expiration
09-25-2025
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 61958-1402-1 identifies a specific commercial package of 30 tablet, film coated in 1 bottle of Tybost, labeled by Gilead Sciences, Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Gilead Sciences, Inc. on June 20, 2025. The current certification is valid through September 25, 2025.

How is this Gilead Sciences, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 61958140201. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
61958-1402-1
11-Digit CMS (5-4-2)
61958-1402-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.